Linda Joosten

Chapter 1 General introduction: management of patients with atrial fibrillation	9
Chapter 2 Atrial fibrillation: a systemic cardiovascular disease in need for integrated cardiovascular risk management	19
Chapter 3 Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients	29
Chapter 4 Stroke rate variation and anticoagulation benefit in atrial fibrillation	57
Chapter 5 Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community	63
Chapter 6 Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial	85
Chapter 7 Safety of switching from a vitamin K antagonist to a non vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomised controlled trial	105
Chapter 8 Clinical consequences of off-label reduced dosing of non vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis	133
Chapter 9 General discussion: from management of patients with atrial fibrillation to the ‘inverse research law’	177
Appendices	193
Summary	193
Samenvatting	203
Dankwoord	213
About the author	221
Publications and conference presentations	225

Made with FlippingBook

RkJQdWJsaXNoZXIy MTk4NDMw